Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Optimization of Therapeutic Protein PEGylation by Integrating Coarse-grain Simulation and Cell-free Protein Synthesis

Award Number: R15GM164971
ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2026
PERIOD OF PERFORMANCE END DATE: 06/30/2029

Group Awards By:

View Award Description

Optimization of Therapeutic Protein PEGylation by Integrating Coarse-grain Simulation and Cell-free Protein Synthesis - ABSTRACT The development of protein-based therapeutics has ushered in a new era of precision medicine, delivering hope and healing to millions facing severe and life-threatening conditions. Unfortunately, as natural biopolymers, protein therapeutics have fundamental limitations compared to small molecule therapeutics. Specifically, most proteins found outside their native location in the body are degraded, recognized by the immune system, lose stability/function, or are naturally cleared—a fatal flaw for a therapeutic. To overcome these limitations, therapeutic proteins may be functionalized with chemical groups to obscure their identity or increase stability. In 1990, the FDA first approved the covalent attachment of the polymer polyethylene glycol (PEG) to therapeutic proteins towards this end. When done properly, PEGylation improves the pharmacokinetic half-life, provides some masking from the immune system, and reduces side effects due to lower dosage frequency. The problem is that PEG attachment can only be done with certain amino acids (e.g. lysine, N-terminus), so control is very limited. Additionally, covalently attaching a PEG molecule to a protein is complex because this chemical modification alters the interactions and positions of the amino acid side chains, disrupting protein function. This disruption commonly outweighs the benefit, such that only 3% of FDA approved therapeutic proteins are PEGylated. This work seeks to greatly expand the benefit of PEGylating protein therapeutics by combining state of the art, computationally efficient coarse-grain molecular simulations with rapid cell-free protein synthesis and site- specific functionalization. Preliminary results have demonstrated that this simulation approach can predict with significant accuracy the optimal amino acid among the hundreds in a protein to target for PEGylation. Additionally, the cell-free protein synthesis approach allows for site-specific incorporation of a uniquely functionalized unnatural amino acid at any desired position—a capability which enables site-specific optimization of PEGylation and is crucial to broad application of the method. Using a design-build-test-learn strategy, parameterization of PEG-amino acid interactions will be incorporated into the simulation for the first time, which is hypothesized to greatly increase its accuracy. This approach will be validated with two protein therapeutics which have not yet been optimally PEGylated (Onconase for Mesothelioma/Ebola Virus Disease treatment and Crisantaspase for Acute Lymphoblastic Leukemia treatment) to improve their efficacy by increasing their activity, stability and retention.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $558,383 )
2026	2026	BRIGHAM YOUNG UNIVERSITY	A-153 ASB	PROVO	UT	84602	UTAH	USA	Biomedical Research and Research Training	000	1	6/30/2026	NEW	$558,383
														Subtotal = $558,383

Grand Total All Awards = $558,383

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Optimization of Therapeutic Protein PEGylation by Integrating Coarse-grain Simulation and Cell-free Protein Synthesis

Award Number: R15GM164971

ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2026

PERIOD OF PERFORMANCE END DATE: 06/30/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer